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Dear Sirs,
As of August 2020, more than 800,000 deaths worldwide 
have been attributed to COVID-19, of which > 41,000 have 
been in the United Kingdom and 2494 in Scotland [1]. Peo-
ple with MND (pwMND) may be particularly vulnerable. 
We completed a population-based analysis of the Scottish 
MND Register, CARE-MND [2] and a clinician survey, to 
measure the impact of the pandemic on (1) diagnostic rate, 
(2) mortality rate, and, (3) delivery of services.
We compared all-cause mortality between 01/03–01/06 
in 2015–2019 (comparator period) and 01/03–01/06 2020 
(COVID-19 period) using multivariable Poisson regres-
sion including age (< 50, 50–70, > 70  years) and year 
(2015–2020) as independent variables. The regression coef-
ficients for 2015–2019 were pooled in a generic inverse vari-
ance random effects model to yield a summary coefficient. 
We performed Chi-squared test to compare socioeconomic 
status (SIMD) [3] between those who died and survivors 
during the COVID-19 period.
To investigate the impact of the pandemic on care deliv-
ery, we undertook a structured online survey of MND 
healthcare professionals focussing on their access to diag-
nostics and interventions; the survey comprised multiple 
choice and free text questions.
We identified 1062 pwMND, diagnosed between 
01/01/2015–01/06/2020 (median age 68 [IQR 60–75], 632 
(59.5%) male). Most (723, 77.7%) had amyotrophic lateral 
sclerosis.
The number of new diagnoses remained constant after 
2016 (range 42–45). Two pwMND, both with progressive 
muscular atrophy, died with confirmed or suspected COVID-
19. One person had an ALSFRS-R 36/48 in July 2020, did 
not use non-invasive ventilation and died unexpectedly. The 
other person had an ALSFRS-R of 20/48 in January 2020 
and used non-invasive ventilation continuously.
There was no difference in all-cause mortality between 
the COVID-19 and comparator periods (pooled regression 
coefficient 1.09 95% CIs 0.78, 1.53; P = 0.61). The mortal-
ity rate per 1000 cases was 114 (37/323) in the COVID-19 
period and 124 in the comparator period (mean, SD 52.9). 
Mortality was higher above 70 years age (1.48 95% CI 1.10, 
1.99; P = 0.009) and lower below 50 years age (0.41 95% CIs 
0.19, 0.80; P = 0.017, Fig. 1a). There were no differences in 
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socioeconomic index in those who died compared to survi-
vors (SIMD 1&2: 38.8% vs. 34.5%; P = 0.42).
Nine consultants and seven nurse specialists completed 
the survey (representing 13/14 Scottish health boards). The 
majority reported provision of gastrostomy (75%), respira-
tory function testing (69%), and non-invasive ventilation 
(56%) were adversely affected. Riluzole prescription (100%), 
palliative care (88%), and end-of-life care (81%) were com-
paratively unaffected (Fig. 1b). Most reported reduced abil-
ity for face-to-face review. Opinions about whether vide-
oconferencing was an acceptable substitute were divided 
(strongly agree/agree 43%, strongly disagree/disagree 38%, 
remainder undecided).
Clinicians additionally reported 70–90% of pwMND were 
shielding, and that pwMND expressed heightened anxiety 
of being exposed to COVID-19, experienced difficulties in 
receiving support from professional carers and family, felt 
loneliness, and fears of being denied treatment.
Our study is the first to demonstrate at a national level 
that rates of new MND diagnoses and all-cause mortality 
in pwMND have thus far been unaffected by COVID-19. 
Shielding recommendations by Scottish government may 
have contributed to the absence of excess mortality. Evalua-
tion of shielding justifies further study including comparison 
with healthcare systems that did not shield. Comparative 
international data on mortality and morbidity in pwMND 
has yet to be published.
Notably, we observed a spike in mortality in 2018, which 
may be linked to a higher than usual rate of new diagnoses 
in 2015.
Our data suggest respiratory function tests, non-invasive 
ventilation and gastrostomy are the worst affected services. 
Preparations for further waves of COVID-19 should prior-
itize maintenance of these. The adverse impact of COVID-
19 on longer-term quality of life, carer burden, morbidity 
and mortality in this vulnerable group requires longitudinal 
evaluation.
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